Pixclara® (18F-⁠FET) Helped Improve Clinical Decision-Making1

Actor portrayals

Real patient case 1: Tumor recurrence vs treatment-related change1

Recurrent glioblastoma, IDH-wildtype, post subtotal resection and chemoradiation

Patient background

  • Male in his 50s with IDH-wildtype, MGMT-unmethylated glioblastoma
  • CNS WHO grade 4
  • Subtotal resection + chemoradiation + 5 cycles of adjuvant temozolomide
  • 8 months later MRI showed an enlarging enhancing lesion with edema, concerning for recurrence vs radiation necrosis

Interpretation of MRI: Lesion was assessed as indeterminate due to discrepancies between the results of conventional imaging and advanced MRI

Pixclara® detected: Residual viable disease (confirmed with biopsy)

Impact on clinical decision-making: PET metabolic activity confirmed viable residual disease, not radiation change. Surgeon proceeded with lesion excision

How did Pixclara® help clinicians?

  • MRI alone could not distinguish recurrence from pseudoprogression
  • Pixclara® clarified the MRI findings by indicating tumor progression vs radiation necrosis. Surgeon proceeded with re-resection

MRI follow-up

5 months before PET

(arrow showing enhancing lesion)

Conventional imaging

MRI follow-up

1.5 months before PET

(arrow showing enhancing lesion)

Conventional imaging

rCBV perfusion2

MRI follow-up
(arrow showing enhancing lesion)

PET: Lesion TBRmax = 4.66
TBRmean = 2.14

Scan with Pixclara®
confirming recurrent tumor

Biopsy confirmed recurrent glioblastoma

Real patient case 2: Tumor recurrence vs treatment-related change1

Recurrent glioblastoma, IDH-wildtype, post gross total resection, chemoradiation, and adjuvant temozolomide

Patient background

  • Male in his 70s with glioblastoma, MGMT-unmethylated
  • CNS WHO grade 4
  • Gross total resection 13 months earlier
  • Radiation completed 12 months earlier with temozolomide
  • Adjuvant temozolomide completed 6 months earlier
  • MRI raised concern for recurrent disease

Interpretation of MRI: Right parietal lesion concerning for recurrent glioblastoma vs treatment-related change before amino acid PET

Pixclara® detected: Residual viable disease, not radiation change (confirmed by biopsy)

Impact on clinical decision-making: Surgeon proceeded to lesion excision

How did Pixclara® help clinicians?

  • MRI enhancement alone could not resolve what part of the lesion represented active tumor vs treatment effect
  • Pixclara® enabled intralesional assessment based on differential uptake, highlighting a small focus suspicious for recurrence and separating it from adjacent treatment-related changes
  • Surgeon proceeded with resection 3 weeks after PET/MRI

MRI follow-up

3 months before PET

(arrow showing enhancing lesion)

Conventional imaging

Conventional imaging scan

MRI follow-up

1 month before PET

(arrow showing enhancing lesion)

Conventional imaging

MRI follow-up scan

rCBV perfusion2

rCBV perfusion scan

MRI follow-up
(arrow showing enhancing lesion)

PET: Lesion TBRmax = 3.23
TBRmean = 2.03

Pixclara® PET scan

Pixclara® scan
confirming tumor

Biopsy confirmed recurrent glioblastoma

Real patient case 3: Tumor recurrence vs post-hemorrhagic or treatment-related change1

Recurrent astrocytoma, IDH-mutant, post subtotal resection and adjuvant vorasidenib

Patient background

  • Female in her 20s with astrocytoma, IDH-mutant, MGMT-unmethylated
  • CNS WHO grade 3
  • Subtotal resection 23 months earlier
  • Slow progression observed 11 months earlier; vorasidenib initiated
  • Spontaneous intracranial hemorrhage 9 months ago

Interpretation of MRI: Lesion concerning for recurrent disease vs post-hemorrhagic or treatment-related change, with an evolving appearance across serial scans

Pixclara® detected: Distinct residual/recurrent astrocytoma

Impact on clinical decision-making: Surgeon proceeded to lesion excision

How did Pixclara® help clinicians?

  • MRI alone could not distinguish what area of the evolving lesion represented active tumor vs post-hemorrhagic or treatment-related change
  • Pixclara® enabled lesion assessment based on differential 18F-FET uptake, identifying residual/recurrent astrocytoma
  • Surgeon proceeded with resection following imaging results

MRI follow-up

5 months before PET

(arrow showing enhancing lesion)

Conventional imaging

MRI 5 months before PET

MRI follow-up

16 days before PET

(arrow showing enhancing lesion)

Conventional imaging

MRI 16 days before PET

MRI follow-up
(arrow showing enhancing lesion)

PET: Lesion TBRmax = 3.10
TBRmean = 2.15

Pixclara® PET scan

Scan with Pixclara®
confirming recurrent tumor

Biopsy confirmed recurrent/residual astrocytoma

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Evidence NCCN Category 2A recommend 18F-FET PET imaging.3

Learn More

18F-FET, 18F-fluoro-ethyl-tyrosine; CNS, central nervous system; IDH, isocitrate dehydrogenase; MGMT, O6-methylguanine-DNA methyltransferase; MRI, magnetic resonance imaging; NCCN, National Comprehensive Cancer Network; PET, positron emission tomography; rCBV, relative cerebral blood volume; TBRmax, maximum tumor-to-background ratio; TBRmean, mean tumor-to-background ratio; WHO, World Health Organization.